Background: Heart failure is a complex and multifactorial disease that affects millions globally, posing significant challenges to healthcare systems.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

The addition of β-adrenergic antagonists to the treatment regimen for heart failure has validated the neurohormonal hypothesis and provided much-improved outcomes. This benefit had been in ...

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Preliminary findings from an 18-month study on acute coronary syndromes, conducted across several hospitals in Kuwait and ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...